Navigation Links
Egalet Announces Financing to Fund Abuse-Deterrent Medications
Date:9/12/2013

MALVERN, Pa., Sept. 12, 2013 /PRNewswire/ -- Egalet Ltd., a specialty pharmaceutical company developing and planning to commercialize abuse-deterrent oral products for the treatment of pain and other indications, announced today that it has closed a financing of up to $20 million led by Index Ventures with participation from other existing investors.  Egalet has received $10 million initially, with an option for an additional $10 million investment under pre-specified conditions.

Prescription drug abuse became the leading cause of accidental death in the United States in 2008 surpassing deaths caused by automobile accidents.  A 2011 research report prepared by the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services, or SAMHSA, estimated that nearly 35 million Americans have used prescription pain relievers, including opioid-containing drugs, for non-prescription purposes at least once in their lifetime.  As of 2007, the total costs of prescription drug abuse were estimated to be up to $72.5 billion annually for public and private healthcare payors in the United States according to the North American Journal of Managed Care. 

Egalet has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient, or API. Using the Company's proprietary platform, Egalet has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical tampering while also providing tailored release of the API.  Egalet's lead product candidates, Egalet-001 and Egalet 002, are abuse-deterrent, extended-release, oral formulations of commonly prescribed opioids in development for the treatment of moderate to severe pain.  Egalet-001 and Egalet 002, if approved, could fill significant unmet needs in the marketplace.

"With these funds we will be able to begin our pivotal studies for Egalet 001 in the first quarter of 2014," said Bob Radie, Egalet's president and chief executive officer.  "We plan to submit a new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, in the fourth quarter of 2014."

About Egalet Ltd.

Egalet Ltd. is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications.  The company has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient.  Using its proprietary platform, Egalet  has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical tampering while also providing tailored release of the active pharmaceutical ingredient.  The Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles.   The company's goal is to be a leading specialty pharmaceutical company focused on the development, manufacture and commercialization of abuse-deterrent pharmaceutical products.  Please visit www.egalet.com for more information.

Contact:
E. Blair Clark-Schoeb
Tel.: 917-432-9275
Email: blair@biotechcomm.com


'/>"/>
SOURCE Egalet Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Egalet to Present at Life Sciences Europe Conference
2. Egalet Announces Issuance of U.S. Patent
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. Egalet Appoints Stan Musial as CFO
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DIEGO , Feb. 8, 2016 /PRNewswire/--  Cell ... announced that advanced tissue-engineering services are now available ... a groundbreaking new three-dimensional (3D) bioprinting approach called ... 3D Bio Printer , a state-of-the-art robotic system ... has created a powerful pay-for-service bio-printing model that ...
(Date:2/8/2016)... , Feb. 8, 2016 ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Inc., will be speaking on how healthcare companies can use newly released government ... the health of a population and intervene and capture the value they create ...
(Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 ... ... pelvic organ prolapse with the latest techniques and the most minimally invasive approaches. ... pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to the ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
Breaking Medicine News(10 mins):